[
  {
    "ts": "2026-02-24T09:13:11+00:00",
    "headline": "Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate",
    "summary": "Amgen (AMGN) has drawn fresh attention after recent trading left the shares at $379.42, capping a period in which returns over the past month and the past three months have both been positive. See our latest analysis for Amgen. The latest move to $379.42 comes on top of a 10.06% 1 month share price return and a 15.80% year to date share price return. The 1 year total shareholder return of 26.35% and 5 year total shareholder return of 95.51% point to momentum that has built steadily over...",
    "url": "https://finance.yahoo.com/news/amgen-amgn-valuation-check-recent-091311630.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "53627269-07c0-3108-a7a3-1d02e950bf0a",
      "content": {
        "id": "53627269-07c0-3108-a7a3-1d02e950bf0a",
        "contentType": "STORY",
        "title": "Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate",
        "description": "",
        "summary": "Amgen (AMGN) has drawn fresh attention after recent trading left the shares at $379.42, capping a period in which returns over the past month and the past three months have both been positive. See our latest analysis for Amgen. The latest move to $379.42 comes on top of a 10.06% 1 month share price return and a 15.80% year to date share price return. The 1 year total shareholder return of 26.35% and 5 year total shareholder return of 95.51% point to momentum that has built steadily over...",
        "pubDate": "2026-02-24T09:13:11Z",
        "displayTime": "2026-02-24T09:13:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-valuation-check-recent-091311630.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-valuation-check-recent-091311630.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T15:17:55+00:00",
    "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $29.30 as of February 9th. Viking Therapeutics (VKTX) has emerged as a compelling scientific and strategic play in the obesity and metabolic therapy space, particularly following Novo Nordisk’s approval of the Wegovy® Pill, […]",
    "url": "https://finance.yahoo.com/news/viking-therapeutics-inc-vktx-bull-151755126.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "af3e92af-0d0d-33a1-88df-f18a872f5ba8",
      "content": {
        "id": "af3e92af-0d0d-33a1-88df-f18a872f5ba8",
        "contentType": "STORY",
        "title": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $29.30 as of February 9th. Viking Therapeutics (VKTX) has emerged as a compelling scientific and strategic play in the obesity and metabolic therapy space, particularly following Novo Nordisk’s approval of the Wegovy® Pill, […]",
        "pubDate": "2026-02-24T15:17:55Z",
        "displayTime": "2026-02-24T15:17:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c6d4a7c11a19d74dca0b695c76ba4538",
          "originalWidth": 848,
          "originalHeight": 565,
          "caption": "Danaher (DHR) Surges as Pharma Tariffs to Benefit Firm",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jFffQa1vPhjtU5jKm85jRQ--~B/aD01NjU7dz04NDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c6d4a7c11a19d74dca0b695c76ba4538.cf.webp",
              "width": 848,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bpPtQ_RSUyNTG_Ooj8w4SA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c6d4a7c11a19d74dca0b695c76ba4538.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viking-therapeutics-inc-vktx-bull-151755126.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viking-therapeutics-inc-vktx-bull-151755126.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "149905998.SW"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]